howard (jack) west, md, regarding tumor mutation burden (tmb) as a biomarker for nsclc patients
Published 6 years ago • 50 plays • Length 3:20
Download video MP4
Download video MP3
Similar videos
-
4:12
tumor mutation burden as a biomarker in nsclc
-
4:21
howard (jack) west, md, regarding the combination of immunotherapy & chemotherapy in nsclc
-
1:08
sai-hong ignatius ou, md, phd, comments on tumor mutation burden (tmb) as a biomarker in nsclc
-
0:38
joan schiller, md, considers the validity of tumor mutation burden (tmb) as a biomarker
-
1:20
benjamin philip levy, md, on tumor mutation burden (tmb) as a biomarker in nsclc
-
2:28
howard (jack) west, md, regarding pdl-1 expression and nsclc
-
1:25
tumor mutational burden (tmb): a predictive biomarker for lung cancer immunotherapy response
-
3:13
howard (jack) west, md, discusses key takeaways from the impower150 study in nsclc
-
2:08
howard (jack) west, md, on treatment options for patients who progress on i-o & chemotherapy
-
5:40
the role of mutation burden as a biomarker in nsclc
-
2:26
howard (jack) west, md, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab
-
2:42
tumor mutation burden (tmb)- a biomarker for cancer immunotherapy!
-
1:47
howard (jack) west, m.d.
-
1:52
howard (jack) west, m.d., at #asco20
-
4:01
locally advanced nsclc: looking ahead
-
2:07
dr. west on advancements for patients with t790m-mutant nsclc
-
28:55
immunotherapy in lung cancer with dr. jack west, part 2
-
1:05
why is standardisation so important for the tumor mutation burden (tmb) biomarker?
-
5:25
optimizing the pacific regimen
Clip.africa.com - Privacy-policy